Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of M1095 versus placebo in moderate to severe chronic plaque psoriasis
2017-004611-38Phase 2Completed
- Sponsor
- Bond Avillion 2 Development LP
- Start
- Jul 2018
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonelokimab in psoriasis and plaque psoriasis (6 arms), sponsored by Bond Avillion 2 Development LP. Primary endpoint: Primary efficacy endpoint. Started Jul 2018; status: completed.
02
Drugs
sonelokimab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2017-004611-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004611-38.